Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS [Protocol]: a systematic review and network meta-analysis

TY - JOUR

T1 - Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS [Protocol]

T2 - a systematic review and network meta-analysis

AU - Oba, Yuji

AU - Patel, Tarang

AU - Anwer, Sumayya

AU - Maduke, Tinashe

AU - Dias, Sofia

N1 - Funding Information: Thank you to Elizabeth Stovold for assisting with the search strategy. The authors and the Cochrane Airways Editorial Team are grateful to the following peer and consumer reviewers for their time and comments. Stella Le, Australia Alan Kaplan, University of Toronto, Canada Linjie Zhang, Federal University of Rio Grande, Brazil Kerry Dwan, Cochrane, UK Sarah Hodgkinson, UK Joshua Cheyne, University of Edinburgh, UK R Akilesh, India Sandra Moroz, Canada Zoe Kopsaftis, The Queen Elizabeth Hospital, Australia Stella Le, Australia Alan Kaplan, University of Toronto, Canada Linjie Zhang, Federal University of Rio Grande, Brazil Kerry Dwan, Cochrane, UK Sarah Hodgkinson, UK Joshua Cheyne, University of Edinburgh, UK R Akilesh, India Sandra Moroz, Canada Zoe Kopsaftis, The Queen Elizabeth Hospital, Australia The Background and Methods sections of this protocol are based on a standard template used by Cochrane Airways. This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Airways. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. Funding Information: This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Airways. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health. Publisher Copyright: Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PY - 2020/11/23

Y1 - 2020/11/23

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To conduct NMAs to compare effectiveness and tolerability of adding a LABA or LAMA to existing ICS therapy versus doubling the dose of ICS in adolescents and adults with uncontrolled asthma who have been treated with or are eligible for LABA/ICS combination therapy.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To conduct NMAs to compare effectiveness and tolerability of adding a LABA or LAMA to existing ICS therapy versus doubling the dose of ICS in adolescents and adults with uncontrolled asthma who have been treated with or are eligible for LABA/ICS combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=85103024561&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD013797

DO - 10.1002/14651858.CD013797

M3 - Article

AN - SCOPUS:85103024561

SN - 1465-1858

VL - 2020

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 11

M1 - CD013797

ER -